Medios AG Q3 2026 Earnings Recap

Medios fell 0.4% after the earnings update, a roughly flat reaction to nine-month revenue growth of 6.7% and confirmed 2026 guidance. The picture is mixed: pricing pressure and higher international material costs weighed on profitability, with EBITDA pre margin down to 4.1% from 4.6% a year earlier.

Key Takeaways

• Nine-month revenue was EUR 1.633 billion, up 6.7% year over year; all three segments contributed to growth.
• EBITDA pre was EUR 66.7 million, and the company said it remained within expectations. EPS was EUR 1.35.
• Pharmaceutical supply revenue grew 6.8%, but pricing pressure reduced its margin; international business also faced lower margins and temporarily higher material costs.
• Patient-specific therapies revenue grew 8.4%; management said the German segment’s EBITDA pre margin returned to double digits.
• Management confirmed adjusted 2026 guidance, saying efficiency measures are expected to offset the Hilfstaxe impact in Q4.